We are live on ! Find out more
ATXI

Avenue Therapeutics, Inc. Common Stock
ATXI

Delisted

ATXI was delisted on the 18th of March, 2025.

Back to rankings

19 hedge funds and large institutions have $17.6M invested in Avenue Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

46% more funds holding

Funds holding: 13 → 19 (+6)

17% more capital invested

Capital invested by funds: $15.1M → $17.6M (+$2.51M)

Holders
19
Holders Change
+6
Holders Change %
+46.15%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
7
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.24M
2
Millennium Management
Millennium Management
New York
+$631K
3
KCM
Kennedy Capital Management
Missouri
+$491K
4
Renaissance Technologies
Renaissance Technologies
New York
+$481K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$180K

Top Sellers

Rank Fund Capital Flow
1
FWM
Frontier Wealth Management
Missouri
-$192K
2
AWS
AJ Wealth Strategies
New York
-$189K
3
6CM
683 Capital Management
New York
-$131K
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
1
Opaleye Management
Massachusetts
$9.25M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$2.75M +$1.24M +124 +83%
EI
3
EAM Investors
California
$861K +$40.1K +4 +5%
BRWA
4
B. Riley Wealth Advisors
Florida
$859K +$170K +17 +25%
Millennium Management
5
Millennium Management
New York
$631K +$631K +63 New
Geode Capital Management
6
Geode Capital Management
Massachusetts
$626K +$20K +2 +3%
Renaissance Technologies
7
Renaissance Technologies
New York
$597K +$481K +48 +436%
KCM
8
Kennedy Capital Management
Missouri
$492K +$491K +49 New
BlackRock
9
BlackRock
New York
$420K +$30.1K +3 +8%
Osaic Holdings
10
Osaic Holdings
Arizona
$302K +$301K +30 New
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$181K +$180K +18 New
Squarepoint
12
Squarepoint
New York
$174K +$170K +17 New
Goldman Sachs
13
Goldman Sachs
New York
$138K +$140K +14 New
Northern Trust
14
Northern Trust
Illinois
$130K – – –
Bank of America
15
Bank of America
North Carolina
$63K +$60.1K +6 New
Morgan Stanley
16
Morgan Stanley
New York
$42K +$10K +1 +33%
Victory Capital Management
17
Victory Capital Management
Texas
$22K +$20K +2 New
UBS Group
18
UBS Group
Switzerland
$18K – – –
Citigroup
19
Citigroup
New York
$10K +$10K +1 New
TRCT
20
Tower Research Capital (TRC)
New York
$1K – – –
FWM
21
Frontier Wealth Management
Missouri
– -$192K -18 Closed
AWS
22
AJ Wealth Strategies
New York
– -$189K -17 Closed
6CM
23
683 Capital Management
New York
– -$131K -12 Closed

ATXI Hedge Fund Activity: Q1 2020 in Review

19 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q1 2020, worth a combined $17.6M — up 17% from $15.1M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new ATXI positions and 3 closed out — a net gain of 6 holders — while 7 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.24M. The largest seller was Frontier Wealth Management, exiting entirely with an estimated $192K sold.

  • 19 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q1 2020, up from 13 in Q4 2019.
  • Funds reported $17.6M of Avenue Therapeutics, Inc. Common Stock stock for Q1 2020, up 17% quarter-over-quarter.
  • 9 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q1 2020 and 3 closed out, a net change of +6 holders.
  • The largest Avenue Therapeutics, Inc. Common Stock buyer in Q1 2020 was Vanguard Group, an estimated $1.24M added.
  • The largest Avenue Therapeutics, Inc. Common Stock seller in Q1 2020 was Frontier Wealth Management, an estimated $192K sold.

Based on aggregated 13F filings for Q1 2020.